Common TitleHBV-10: Heplisav-B versus Engerix-B in Healthy Adults 18-55 Years of Age
Official Title A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®
Phase Phase III
ClinicalTrials.gov NCT00435812
Treatments
Heplisav-B
Heplisav-B
Tradename:Heplisav-BOther Names:Hepatitis B Vaccine (Recombinant) Adjuvanted, HepB-CpGClass:Vaccines (HBV)Funding
IndustryDynavax Technologies Corporation